Puma Biotechnology Inc (PBYI) Financial Statements (2026 and earlier)

Company Profile

Business Address 10880 WILSHIRE BLVD.
LOS ANGELES, CA 90024
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:91,62786,83848,91646,54669,84993,389
Cash and cash equivalent29,63569,21984,58576,20163,13185,293
Short-term investments67,89331,74611,3544,87318,9758,096
Other undisclosed cash, cash equivalents, and short-term investments(5,901)(14,127)(47,023)(34,528)(12,257) 
Restricted cash and investments2,091   8,8508,850
Receivables53,65432,01147,83740,35032,52625,543
Inventory, net of allowances, customer advances and progress billings5,5158,7247,0804,5267,1093,454
Inventory5,5158,7247,0804,5267,1093,454
Prepaid expense3,6425,8674,4175,9028,98411,262
Deferred rent asset      198
Other current assets256919122,4294473,443
Other undisclosed current assets5,90114,12747,02334,52812,257 
Total current assets:162,686147,658156,185134,281140,022146,139
Noncurrent Assets
Operating lease, right-of-use asset5,3734,5797,79211,36214,01716,404
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization1875158551,1461,7562,481
Intangible asset, including goodwill, after accumulated amortization41,39251,13160,87170,61066,12574,140
Intangible asset, excluding goodwill, after accumulated amortization41,39251,13160,87170,61066,12574,140
Prepaid expense2,6731192,5242,069611 
Restricted cash and investments  2,0912,0912,5913,3113,311
Deferred income tax assets3,8307,075    
Other undisclosed noncurrent assets161165210 7431,745
Total noncurrent assets:53,61665,67574,34387,77886,56398,081
TOTAL ASSETS:216,302213,333230,528222,059226,585244,220
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities55,08742,40759,61059,474103,74973,401
Accounts payable5,0565,5096,8896,44011,17412,076
Accrued liabilities50,03136,89852,72153,03492,57561,325
Debt22,52345,32933,997  14,286
Other liabilities142     
Other undisclosed current liabilities3,5018,3755,77518,0105,83726,568
Total current liabilities:81,25396,11199,38277,484109,586114,255
Noncurrent Liabilities
Long-term debt and lease obligation  21,71965,65998,307113,067103,574
Long-term debt, excluding current maturities  21,71965,65998,30797,09284,025
Liabilities, other than long-term debt4,7091,7367,15511,87137233
Accounts payable and accrued liabilities  1211213737233
Other liabilities  121    
Operating lease, liability4,7091,4947,03411,83415,97519,549
Other undisclosed noncurrent liabilities  1,6424,89012,7896,34132,109
Total noncurrent liabilities:4,70925,09777,704122,967119,445135,916
Total liabilities:85,962121,208177,086200,451229,031250,171
Equity
Equity, attributable to parent130,34092,12553,44221,608(2,446)(5,951)
Common stock555544
Additional paid in capital1,414,0741,407,0001,398,6051,388,3581,364,3091,331,676
Accumulated other comprehensive income (loss)366(4) (2) 
Accumulated deficit(1,283,775)(1,314,886)(1,345,164)(1,366,755)(1,366,757)(1,337,631)
Total equity:130,34092,12553,44221,608(2,446)(5,951)
TOTAL LIABILITIES AND EQUITY:216,302213,333230,528222,059226,585244,220

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues228,371230,468235,637228,031253,155225,110
Cost of revenue
(Cost of Product and Service Sold)		(58,157)(64,404)(62,682)(55,093)(63,701) 
Gross profit:170,214166,064172,955172,938189,454225,110
Operating expenses(132,915)(135,098)(140,315)(149,218)(188,164)(255,512)
Operating income (loss):37,29930,96632,64023,7201,290(30,402)
Nonoperating income (expense)(1,517)(6,866)(9,966)785(30,092)(29,386)
Investment income, nonoperating4,0784,7242,605813160489
Other nonoperating income (expense)1,027862759(28)292367
Interest and debt expense(6,622)(12,452)(13,330)(11,592)(8,146)(14,046)
Income (loss) from continuing operations before equity method investments, income taxes:29,16011,6489,34412,913(36,948)(73,834)
Other undisclosed income (loss) from continuing operations before income taxes6,62212,45213,330(12,456)8,14614,046
Income (loss) from continuing operations before income taxes:35,78224,10022,674457(28,802)(59,788)
Income tax expense (benefit)(4,671)6,178(1,083)(455)(324)(207)
Income (loss) from continuing operations:31,11130,27821,5912(29,126)(59,995)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(29,126)(59,995)
Net income (loss) available to common stockholders, diluted:31,11130,27821,5912(29,126)(59,995)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net income (loss):31,11130,27821,5912(29,126)(59,995)
Comprehensive income (loss):31,11130,27821,5912(29,126)(59,995)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent3010(4)2(2)(62)
Comprehensive income (loss), net of tax, attributable to parent:31,14130,28821,5874(29,128)(60,057)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: